On 6 January 2021, orphan designation EU/3/20/2385 was granted by the European Commission to Mundipharma Corporation (Ireland) Limited, Ireland, for rezafungin acetate for the treatment of invasive candidiasis.
Treatment of invasive candidiasis
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
|June 2022||The sponsorship was transferred from Mundipharma Corporation (Ireland) Limited to Mundipharma GmbH, Germany|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: